Company intelligence / Profile preview
Prescient Therapeutics
Melbourne, Victoria, Australiaptxtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Prescient Therapeutics is currently developing PTX-100, which has received FDA clearance for Phase 2 trials. The company focuses on personalized medicine approaches, including targeted and cell therapies.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small moleculesCAR-T cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaborations with Yale UniversityUniversity of PennsylvaniaOxford UniversityMoffitt Cancer CenterPeter MacCallum Cancer Centre
Beyond the preview
Go deeper on Prescient Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prescient Therapeutics.